About
BrainStorm Cell Therapeutics is pioneering the field of neurodegenerative disease treatment with a strong focus on amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). At the heart of BrainStorm's innovative approach is NurOwn®, a breakthrough technology that transforms autologous mesenchymal stem cells into neurotrophic factor-secreting cells. This unique process is designed to deliver critical growth factors directly to areas affected by neurodegenerative conditions, offering new hope for patients with ALS and MS.
Recent strategic developments at BrainStorm highlight the company's commitment to overcoming the challenges of neurodegenerative diseases. Through ongoing engagement with regulatory authorities, BrainStorm is dedicated to advancing NurOwn® and ensuring it meets the rigorous standards for efficacy and safety. The company's proactive and collaborative approach with regulatory bodies underscores its dedication to bringing NurOwn® to patients in need.
In response to the evolving landscape of therapeutic development, BrainStorm has undertaken a strategic realignment to accelerate the development of NurOwn® for both ALS and MS. This includes streamlining operations and focusing resources on critical aspects of clinical trials and regulatory submissions, ensuring that BrainStorm remains at the forefront of innovation in treating neurodegenerative diseases.
For the latest information on BrainStorm's efforts and developments in ALS and MS treatment, please visit the BrainStorm [website](https://www.ir.brainstorm-cell.com) or review detailed articles from reputable news sources that cover these significant advancements.
Funding history · 4 rounds · $55.2M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What was a significant regulatory development for BrainStorm's NurOwn® program in February 2020?
- In February 2020, BrainStorm Cell Therapeutics and the FDA reached an agreement on a potential regulatory pathway for NurOwn®'s approval in ALS.
- What was the outcome of the FDA Advisory Committee meeting regarding NurOwn® for ALS in September 2023?
- In September 2023, an FDA advisory panel voted against recommending the approval of NurOwn® for ALS, leading BrainStorm to withdraw its approval application in October 2023.
- What strategic realignment did BrainStorm undertake in October 2023?
- In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize NurOwn® for the treatment of ALS.
- What was the latest financing round for BrainStorm, and who was a lead investor?
- BrainStorm's latest financing round was a $10 million PIPE in March 2020, with ABBHI INVESTMENTS, LLC as an investor. For full financing history, please refer to startupim.
- What was a key manufacturing partnership secured by BrainStorm in May 2025?
- In May 2025, BrainStorm secured a manufacturing partnership with Minaris for the upcoming NurOwn® Phase 3b ALS clinical trials.
- What was the regulatory status of BrainStorm's Phase 3b trial for NurOwn® in ALS in May 2025?
- In May 2025, BrainStorm received FDA clearance to initiate the Phase 3b trial of NurOwn® for ALS.
- What was the outcome of BrainStorm's Nasdaq listing status in July 2025?
- In July 2025, BrainStorm Cell Therapeutics announced its Nasdaq delisting and transition to OTCQB.
- What was a significant patent development for BrainStorm in December 2024?
- In December 2024, BrainStorm strengthened its exosome patent portfolio by receiving a Notice of Allowance for a U.S. patent covering its platform technology.
- What was the total amount of grants received by BrainStorm from the IIA in 2020?
- In 2020, BrainStorm received a total of $2 million in grants from the Israel Innovation Authority (IIA).